

Association of Ambulatory Use of Statins and Beta-Blockers with Long-Term Mortality after Vascular Surgery

Thomas W. Barrett, MD¹
 Motomi Mori, PhD²
 David De Boer, MS³

¹ Portland Veterans Affairs Medical Center, Section of General Medicine; Oregon Health & Science University, Division of General Internal Medicine and Geriatrics, Portland, Oregon

² Oregon Health & Science University, Department of Public Health and Preventive Medicine, Division of Biostatistics, Portland, Oregon

³ Oregon Health & Science University, Center for Biostatistics Computing and Informatics in Biology and Medicine, Portland, Oregon

BACKGROUND: The use of drugs to improve postoperative outcomes has focused on short-term end points and centered on beta-blockers. Emerging evidence suggests statins may also improve postoperative outcomes.

OBJECTIVE: We sought to ascertain if the ambulatory use of statins and/or beta-blockers was associated with a reduction in long-term mortality after vascular surgery.

DESIGN: Retrospective cohort study with a median follow-up of 2.7 years.

SETTING: Regional multicenter study at Veterans Affairs medical centers.

PATIENTS: Three thousand and sixty-two patients presenting for vascular surgery.

MEASUREMENTS: Patients were categorized as using statins or beta-blockers if they filled a prescription for the study drug within 30 days of surgery. Survival analyses, propensity score methods, and stratifications by the revised cardiac risk index (RCRI) were performed.

RESULTS: Propensity-adjusted ambulatory use of statins and beta-blockers was associated with a reduction in mortality over the study period compared with nonuse of these medications hazard ratio [HR] = 0.78 [95% CI: 0.67-0.92], $P = .0021$, and number needed to treat (NNT) = 22 for statins; HR = 0.84 [95% CI: 0.73-0.96], $P = .0106$, and NNT = 30 for beta-blockers. In addition, for propensity-adjusted use of both statins and beta-blockers compared with neither the HR was 0.56 [95% CI: 0.42-0.74] $P < .0001$, and NNT was 9. The RCRI confirmed combination statin and beta-blocker use was beneficial at all levels of risk. Use of the combination study drugs by the highest-risk patients was associated with a 33% decrease in mortality after 2 years ($P = .0106$).

CONCLUSIONS: The use of ambulatory statins alone or in combination with beta-blockers is associated with a reduction in long-term mortality after vascular surgery, and combination use benefits patients at all levels of risk. *Journal of Hospital Medicine* 2007;2:241-252. © 2007 Society of Hospital Medicine.

KEYWORDS: vascular surgery, beta-blockers, statins, mortality.

Vascular surgery has higher morbidity and mortality than other noncardiac surgeries. Despite the identification of vascular surgery as higher risk, 30-day mortality for this surgery has remained at 3%-10%. Few studies have examined longer-term outcomes, but higher mortality rates have been reported, for example, 10%-30% 6 months after surgery, 20%-40% 1 year after surgery, and 30%-50% 5 years after surgery.¹⁻⁵ Postoperative adverse events have been found to be highly correlated with perioperative ischemia and infarction.⁶⁻⁸ Perioperative beta-blockers have been widely studied and have been shown to benefit patients undergoing noncardiac surgery generally and vascular surgery

The authors thank LeAnn Snodgrass for assistance with data extraction and management. This work was funded by the Oregon Health & Science University Medical Research Foundation.

specifically.^{9,10} However, 2 recent trials of perioperative beta-blockers in noncardiac and vascular surgery patients failed to show an association with 18-month and 30-day postoperative morbidity and mortality, respectively.^{11,12} In addition, the authors of a recent meta-analysis of perioperative beta-blockers suggested more studies were needed.¹³ Furthermore, there have been promising new data on the use of perioperative statins.¹⁴⁻¹⁸ Finally, as a recent clinical trial of revascularization before vascular surgery did not demonstrate an advantage over medical management, the identification of which perioperative medicines improve postoperative outcomes and in what combinations becomes even more important.¹⁹ We sought to ascertain if the ambulatory use of statins and/or beta-blockers within 30 days of surgery was associated with a reduction in long-term mortality.

METHODS

Setting and Subjects

We conducted a retrospective cohort study using a regional Department of Veterans Affairs (VA) administrative and relational database, the Consumer Health Information and Performance Sets (CHIPs), which automatically extracts data from electronic medical records of all facilities in the Veterans Integrated Services Network 20, which encompasses Alaska, Washington, Oregon, and Idaho. CHIPs contains information on both outpatient and inpatient environments, and a record is generated for every contact a patient makes with the VA health care system, which includes picking up prescription medications, laboratory values, demographic information, International Classification of Diseases, 9th Revision (ICD-9), codes, and vital status. In addition, we used the Beneficiary Identification and Records Locator Subsystem database, which is the national VA death index and includes Social Security Administration data that has been shown to be 90%-95% complete for assessing vital status.²⁰

Data for all patients who had vascular surgery at 5 VA medical centers in the region from January 1998 to March 2005 was ascertained. If a patient had a second operation within 2 years of the first, the patient was censored at the date of the second operation. A patient was defined as taking a statin or beta-blocker if a prescription for either of these medications had been picked up within 30 days before or after surgery. The IRB at the Portland VA Medical Center approved the study with a waiver of informed consent.

Data Elements

For every patient we noted the type of vascular surgery (carotid, aortic, lower extremity bypass, or lower extremity amputation), age, sex, comorbid conditions (hypertension, cerebrovascular disease, cancer, diabetes, hyperlipidemia, chronic obstructive pulmonary disease [COPD], chronic kidney disease [CKD], coronary artery disease [CAD], heart failure), tobacco use, ethnicity, nutritional status (serum albumin), and medication use, defined as filling a prescription within 30 days before surgery (insulin, aspirin, angiotensin-converting enzyme [ACE] inhibitor, and clonidine). Each patient was assigned a revised cardiac risk index (RCRI) score.²¹ For each the risk factors: use of insulin, CAD, heart failure, cerebrovascular disease, CKD, and high-risk surgery (intrathoracic, intraperitoneal, or suprainguinal vascular procedures) 1 point was assigned. These variables were defined according to ICD-9 codes. CKD was defined as either an ICD-9 code for CKD or a serum creatinine > 2 mg/dL. Patients were identified by the index vascular surgery using ICD-9 codes in the CHIPs database, and both inpatient and outpatient data were extracted.

Statistical Analysis

All patients were censored at the point of last contact up to 5 years after surgery to focus on more clinically relevant long-term outcomes possibly associated with vascular surgery. We conducted 3 separate analyses: (1) statin exposure regardless of beta-blocker exposure; (2) beta-blocker exposure regardless of statin exposure, and; (3) combined exposure to statins and beta-blockers.

Propensity score methods were used to adjust for imbalance in the baseline characteristics between statin users and nonusers, beta-blocker users and nonusers, and combination statin and beta-blocker users and nonusers.^{22,23} The range of the propensity score distribution was similar in drug users and nonusers in the individual analyses. There was sufficient overlap between the 2 groups in each stratum. To derive propensity scores for the individual drug analyses, statin use and beta-blocker use were modeled independently with the demographic and clinical variables using stepwise logistic regression with a relaxed entry criterion of $\alpha = 0.20$. Only 1 variable (hyperlipidemia) remained significantly different between statin users and nonusers, and it was included in the subsequent analyses as a potential confounder. The variable

albumin had 511 missing values. To keep this variable in the propensity scores, the missing values were replaced by the predicted values of albumin from the multiple linear regression model that included the other demographic variables. The propensity scores were grouped into quintiles and used as a stratification variable in the subsequent analyses. To confirm that the propensity score method reduced the imbalances, the demographic and clinical characteristics of statin and beta-blocker users and nonusers and combination users and nonusers were compared using Cochran-Mantel-Haenzel tests with the respective propensity score as a stratification variable.

For the combined use of both study drugs, we performed univariate analysis with adjustment only for RCRI (as this was a powerful predictor of mortality in our dataset; Table 1) as well as a propensity score analysis in an exploratory manner. There have been limited applications of propensity score methods to multiple treatment groups. Similar to that in the study by Huang et al.,²⁴ we developed a multinomial baseline response logit model to obtain 3 separate propensity scores (statin only vs. none, beta-blocker only vs. none, and both vs. none). Because of the limited sample size, the data were stratified according to the median split of each propensity score. Each score had similar ranges for each treatment group. All but 5 variables (CAD, hypertension, hyperlipidemia, ACE inhibitor use, and type of surgery) were balanced after accounting for strata. These 5 variables were then included in the final stratified Cox regression model as potential confounders.

To comment on patient-specific risk by stratification with the RCRI, we used a fixed time point of the 2-year mortality estimated from the Cox regression model to analyze use of study drugs singly or in combination compared with use of neither.

Chi-square tests were used to categorize and compare demographic and clinical characteristics of statin users and nonusers, of beta-blocker users and nonusers, and combination users and nonusers. Survival curves were estimated using the Kaplan-Meier method and compared using the log-rank test. Stratified or unstratified Cox regression was used to estimate the hazard ratios of statins and beta-blockers, with or without adjustment for the propensity score. All analyses were performed using SAS (Statistical Analysis System) software, version 9.1.

RESULTS

Patient Characteristics

The study included 3062 patients whose median age was 67 (interquartile range, 59-74; Table 1). Ninety-nine percent of the study patients were men. Overall, ambulatory use of statins and beta-blockers was found in 44% and 53% of patients, respectively, and combination use occurred in 30%. Sixty-one percent of patients had an RCRI of 1 or greater; among them 71% were statin users (Table 2), 68% were beta-blocker users (Table 3), and 75% were combination users (Table 4). Sixty-four percent of surgeries were either lower extremity bypass or amputation, 29% were carotid, and 8% aortic. Median follow-up for all patients was 2.7 years (interquartile range, 1.2-4.6). Of the whole study cohort, 53% and 62% filled a prescription for a statin or beta-blocker within 1 year of surgery, respectively, and 58% and 67% filled a prescription within 2 years of surgery, respectively. Overall mortality at 30 days was 3%, at 1 year 14%, and at 2 years 22%.

Univariate Survival Analysis

Univariate Cox regression analysis revealed a strong effect of the composite RCRI, which was predictive of mortality in a linear fashion over the course of the study compared with an RCRI of 0 (Table 1). Univariate analysis showed significant associations with decreased mortality for statins (hazard ratio [HR] = 0.66 [95% CI 0.58-0.75], $P < .0001$) and beta-blockers (HR = 0.74 [95% CI 0.66-0.84], $P = .0001$); see Table 1. Of note, compared with that in 1998, mortality did not change for all the years for which data were complete. In addition, compared with taking neither study drug, taking a statin only, a beta-blocker only, or both was associated with decreased mortality ($P = .0002$, $P = .0079$, and $P < .0001$, respectively; Fig. 1).

Propensity Score Analysis for Single Study Drug

There were significant differences in demographic and clinical characteristics between statin-users versus statin nonusers, and between beta-blocker users versus beta-blocker nonusers. These differences became insignificant after the propensity score adjustment, with the exception of hyperlipidemia for statins, $P = .02$, which was added to the model as a confounder (Table 2). The distribution of the propensity scores was similar for study drug users and nonusers within each stratum. The association with decreased

TABLE 1
Patient Demographics with Univariate Mortality

Variable	Level	N (%) Overall N = 3062	Hazard ratio (95% CI)	Chi-square P value
Age in years, median (IQR)		67 (59-74)	1.04 (1.04, 1.05) ^a	<.0001
Sex	Female	45 (1)	0.89 (0.53, 1.51)	.6704
	Male	3017 (99)	1	1.0000
Preoperative medical conditions	HTN	2415 (79)	1.32 (1.13, 1.55)	.0006
	CVA/TIA	589 (19)	1.05 (0.90, 1.22)	.5753
	CA	679 (22)	1.55 (1.36, 1.78)	<.0001
	DM	1474 (48)	1.75 (1.54, 1.98)	<.0001
	Lipid	872 (28)	0.84 (0.74, 0.97)	.0187
	COPD	913 (30)	1.68 (1.48, 1.90)	<.0001
	CAD	1491 (49)	1.46 (1.29, 1.66)	<.0001
	CHF	747 (24)	2.44 (2.15, 2.77)	<.0001
	CKD	443 (14)	2.32 (2.00, 2.69)	<.0001
Blood chemistry	Creatinine > 2	229 (7)	2.73 (2.28, 3.28)	<.0001
	Albumin ≤ 3.5	596 (23)	2.70 (2.35, 3.10)	<.0001
Medication use	Aspirin	1789 (58)	1.10 (0.97, 1.25)	.1389
	ACE inhibitor	1250 (41)	0.93 (0.82, 1.06)	.2894
	Insulin	478 (16)	1.31 (1.12, 1.54)	.0007
	Clonidine	115 (4)	1.68 (1.29, 2.20)	.0001
Perioperative medication	Statin ^b	1346 (44)	0.66 (0.58, 0.75)	<.0001
	Beta-blocker ^c	1617 (53)	0.74 (0.66, 0.84)	<.0001
	Statin only	414 (14)	0.69 (0.56, 0.84)	.0002
	Beta-blocker only	685 (22)	0.81 (0.69, 0.95)	.0079
	Statin and beta-blocker	932 (30)	0.57 (0.49, 0.67)	<.0001
	None ^d	1031 (34)	1	1.0000
Type of surgery	Aorta	232 (8)	1.34 (1.01, 1.77)	<.0001
	Carotid	875 (29)	1	
	Amputation	867 (28)	2.80 (2.36, 3.32)	
	Bypass	1088 (36)	1.57 (1.32, 1.87)	
RCRI	0	1223 (40)	1	<.0001
	1	1005 (33)	1.33 (1.13, 1.55)	
	2	598 (20)	2.22 (1.88, 2.62)	
	3	200 (7)	3.16 (2.54, 3.93)	
	≥4	36 (1)	4.82 (3.15, 7.37)	
Year surgery occurred	1998	544 (18)	1	.6509
	1999	463 (15)	0.91 (0.75, 1.10)	
	2000	420 (14)	0.93 (0.77, 1.13)	
	2001	407 (13)	0.93 (0.75, 1.14)	
	2002	374 (12)	1.12 (0.90, 1.40)	
	2003	371 (12)	1.15 (0.90, 1.47)	
	2004	407 (13)	0.97 (0.72, 1.31)	
	2005	76 (3)	0.68 (0.28, 1.65)	
Tobacco user	Yes	971 (32)	0.90 (0.76, 1.08)	.4762
	No	649 (21)	1	
	Null	1442 (47)	0.96 (0.81, 1.13)	
Ethnicity	White	563 (18)	1	.0366
	Other	39 (1)	0.98 (0.55, 1.76)	
	Unknown	2460 (80)	1.24 (1.05, 1.46)	

RCRI, revised cardiac risk index; HTN, hypertension; CVA/TIA, cerebrovascular disease; CA, cancer, DM, diabetes mellitus; lipid, hyperlipidemia; COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease; CHF, congestive heart failure; CKD, chronic kidney disease; ACE, angiotensin-converting enzyme.

^aIncrease of 4% in mortality per year.

^bStatin users compared to statin nonusers.

^cBeta-blocker users compared to beta-blocker nonusers.

^dNone = not using either statin or beta-blocker.

TABLE 2
Demographic Data for Statin Users Compared with Statin Nonusers

Variable, N (%)	Level	Overall (N = 3062)	Statin users (N = 1346 [44])	Statin nonusers (N = 1716 [56])	Unadjusted P value	Propensity-adjusted P value
Age in years, median (IQR)		67 (59-74)	66 (59-73)	68 (60-75)	<.0001	.9934
Sex	Female	45 (1)	15 (1)	30 (2)	.1480	.7822
	Male	3017 (99)	1331 (99)	1686 (98)		
Preoperative medical conditions	HTN	2415 (79)	1176 (87)	1239 (72)	<.0001	.2984
	CVA/TIA	589 (19)	328 (24)	261 (15)	<.0001	.3935
	CA	679 (22)	307 (23)	372 (22)	.4550	.8404
	DM	1474 (48)	666 (49)	808 (47)	.1883	.5504
	Lipid	872 (28)	629 (47)	243 (14)	<.0001	.0246
	COPD	913 (30)	411 (31)	502 (29)	.4419	.8435
	CAD	1491 (49)	837 (62)	654 (38)	<.0001	.4720
	CHF	747 (24)	370 (27)	377 (22)	.0004	.4839
	CKD	443 (14)	208 (15)	235 (14)	.1698	.9990
Blood chemistry	Creatinine > 2	229 (7)	101 (8)	128 (7)	.9629	.6911
	Albumin ≤ 3.5	596 (23)	191 (16)	405 (30)	<.0001	.5917
Medication use	Aspirin	1789 (58)	904 (67)	885 (52)	<.0001	.6409
	Ace inhibitor	1250 (41)	712 (53)	538 (31)	<.0001	.6075
	Beta-blocker	1220 (40)	767 (57)	453 (26)	<.0001	.4058
	Insulin	478 (16)	254 (19)	224 (13)	<.0001	.7919
	Clonidine	115 (4)	61 (5)	54 (3)	.0454	.6141
Type of surgery	Aorta	232 (8)	106 (8)	126 (7)	<.0001	.9899
	Carotid	875 (29)	510 (38)	365 (21)		
	Amputation	867 (28)	274 (20)	593 (35)		
	Bypass	1088 (36)	456 (34)	632 (37)		
RCRI	0	1223 (40)	389 (29)	834 (49)	<.0001	.9831
	1	1005 (33)	507 (38)	498 (29)		
	2	598 (20)	318 (24)	280 (16)		
	3	200 (7)	109 (8)	91 (5)		
	≥4	36 (1)	23 (1)	13 (0.76)		
Year of surgery	1998	544 (18)	134 (10)	410 (24)	<.0001	1
	1999	463 (15)	163 (12)	300 (17)		
	2000	420 (13)	178 (13)	242 (14)		
	2001	407 (13)	188 (14)	219 (13)		
	2002	374 (12)	194 (14)	180 (10)		
	2003	371 (12)	209 (16)	162 (9)		
	2004	407 (13)	229 (17)	178 (10)		
	2005	76 (3)	51 (4)	25 (1.5)		
Tobacco user	Yes	971 (32)	494 (37)	477 (28)	<.0001	.9809
	No	649 (21)	335 (25)	314 (18)		
	Null	1442 (47)	517 (38)	925 (54)		
Ethnicity	White	563 (18)	263 (20)	300 (17)	.1544	.9475
	Other	39 (1)	13 (1)	26 (1.5)		
	Unknown	2460 (80)	1070 (79)	1390 (81)		

Note: P values for categorical variables were obtained with the chi-square test and for continuous variables with the Wilcoxon rank sum test. Propensity-adjusted P values were derived from Cochran-Mantel-Haenszel statistics.

IQR, interquartile range; RCRI, revised cardiac risk index; HTN, hypertension; CVA/TIA, cerebral vascular disease; CA, cancer; DM, diabetes; lipid, hyperlipidemia; COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease; CHF, congestive heart failure; CKD, chronic kidney disease; ACE, angiotensin-converting enzyme.

mortality remained significant after adjusting for propensity score (for statins, HR = 0.78 [95% CI 0.67-0.92, $P = .0050$], number needed to treat [NNT] = 22; for beta-blockers HR = 0.84 [95% CI 0.73-0.96, $P = .0103$], NNT = 30; Fig. 2).

Combination Study Drugs and Revised Cardiac Risk Index: Univariate Analysis

We wanted our results to closely model those of combination use of the study drugs by patients in a clinical situation. Therefore, we first examined the

TABLE 3
Demographic Data for Beta-Blocker Users Compared with Non-Beta-Blocker Users

Variable, N (%)	Level	Overall N = 3062	BB users N = 1617 (53)	Non-BB users N = 1445 (47)	Unadjusted P value	Propensity-adjusted P value
Age in years, median (IQR)		67 (59-74)	67 (59-75)	68 (60-76)	.0526	.7671
Sex	Female	45 (1)	12 (1)	33 (2)	.0004	.585
	Male	3017 (99)	1605 (99)	1412 (98)		
Preoperative medical conditions	HTN	2415 (79)	1398 (86)	1017 (70)	<.0001	.1837
	CVA/TIA	589 (19)	364 (23)	225 (16)	<.0001	.3206
	CA	679 (22)	359 (22)	320 (22)	.9701	.4288
	DM	1474 (48)	739 (46)	735 (51)	.0043	.6329
	Lipid	872 (28)	555 (34)	317 (22)	<.0001	.7180
	COPD	913 (30)	487 (30)	426 (29)	.7007	.8022
	CAD	1491 (49)	975 (60)	516 (36)	<.0001	.3496
	CHF	747 (24)	439 (27)	308 (21)	.0002	.6509
	CKD	443 (14)	248 (15)	195 (13)	.1480	.8544
Blood chemistry	Creatinine > 2	229 (7)	132 (8)	97 (7)	.1277	.5867
	Albumin ≤ 3.5	596 (23)	252 (18)	344 (30)	<.0001	.5347
Medication use	Aspirin	1789 (58)	1046 (65)	743 (51)	<.0001	.4942
	Ace inhibitor	1250 (41)	760 (47)	490 (34)	<.0001	.4727
	Statin	1220 (40)	932 (58)	414 (29)	<.0001	.3706
	Insulin	478 (16)	255 (16)	223 (15)	.7973	.5991
	Clonidine	115 (4)	77 (5)	38 (3)	.0019	.8241
Type of surgery	Aorta	232 (8)	176 (11)	56 (4)	<.0001	.5664
	Carotid	875 (29)	515 (32)	360 (25)		
	Amputation	867 (28)	339 (21)	528 (37)		
	Bypass	1088 (36)	587 (36)	501 (35)		
RCRI	0	1223 (40)	518 (32)	705 (49)	<.0001	.5489
	1	1005 (33)	583 (36)	422 (29)		
	2	598 (20)	358 (22)	240 (17)		
	3	200 (7)	130 (8)	70 (5)		
	≥4	36 (1)	28 (2)	8 (1)		
Year of surgery	1998	544 (18)	200 (12)	344 (24)	<.0001	.3832
	1999	463 (15)	211 (13)	252 (17)		
	2000	420 (13)	210 (13)	210 (15)		
	2001	407 (13)	209 (13)	198 (14)		
	2002	374 (12)	220 (14)	154 (11)		
	2003	371 (12)	238 (15)	133 (9)		
	2004	407 (13)	279 (17)	128 (9)		
	2005	76 (3)	50 (3)	26 (2)		
Tobacco user	Yes	971 (32)	569 (35)	402 (28)	<.0001	.9025
	No	649 (21)	370 (23)	279 (19)		
	Null	1442 (47)	678 (42)	764 (53)		
Ethnicity	White	563 (18)	309 (19)	254 (18)	.4962	.8762
	Other	39 (1)	19 (1)	20 (1)		
	Unknown	2460 (80)	1289 (80)	1171 (81)		

Note: P values for categorical variables were obtained with the chi-square test and for continuous variables with the Wilcoxon rank sum test. Propensity-adjusted P values were derived from Cochran-Mantel-Haenszel statistics.

IQR, interquartile range; RCRI, revised cardiac risk index; HTN, hypertension; CVA/TIA, cerebral vascular disease; CA, cancer; DM, diabetes; lipid, hyperlipidemia; COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease; CHF, congestive heart failure; CKD, chronic kidney disease; ACE, angiotensin-converting enzyme.

effects of ambulatory statins alone, beta-blockers alone, and a combination of statins and beta-blockers by univariate analysis. Grouping patients by study drug use has not commonly been reported in the literature. We also examined the statistical interaction between the study drugs and the RCRI.

The main-effects model adequately explained all-cause mortality, and the statistical interaction between the study drugs and the RCRI was not significant.

The final univariate Cox regression model, which compared use of a statin alone, a beta-

TABLE 4
Demographic Data for Combination Study Drug Users Compared with Noncombination Study Drug Users

N (%) Variable	Level	Overall N = 3062	BB alone N = 685 (22)	Statin alone N = 414 (14)	Both drugs N = 932 (30)	Neither drug N = 1031 (34)	Unadjusted P value	Propensity-adjusted P value
Age in years, median (IQR)		67 (59-74)	68 (60-75)	67 (60-75)	66 (59-73)	69 (60-76)	.0029	.9824
Sex	Female	45 (1)	7 (1)	10 (2)	5 (1)	23 (2)	.0042	.5815
	Male	3017 (99)	678 (99)	404 (98)	927 (99)	1008 (98)		
Preoperative medical conditions	HTN	2415 (79)	560 (82)	338 (82)	838 (90)	679 (66)	<.0001	.0251
	CVA/TIA	589 (19)	127 (19)	91 (22)	237 (25)	134 (13)	<.0001	.4543
	CA	679 (22)	150 (22)	98 (24)	209 (22)	222 (22)	.8379	.9749
	DM	1474 (48)	291 (43)	218 (53)	448 (48)	517 (50)	.0031	.3943
	Lipid	872 (28)	125 (18)	199 (48)	430 (46)	118 (11)	<.0001	<.0001
	COPD	913 (30)	199 (29)	123 (30)	288 (9)	303 (29)	.8475	.9769
	CAD	1491 (49)	327 (48)	189 (46)	648 (70)	327 (32)	<.0001	<.0001
	CHF	747 (24)	163 (24)	94 (23)	276 (30)	214 (21)	<.0001	.7031
	CKD	443 (14)	92 (13)	52 (13)	156 (17)	143 (14)	.1120	.8364
Blood chemistry	Creatinine > 2	229 (7)	52 (8)	21 (5)	80 (9)	76 (7)	.1619	.7184
	Albumin ≤ 3.5	596 (23)	134 (20)	73 (20)	118 (14)	271 (34)	<.0001	.2846
Medication use	Aspirin	1789 (58)	398 (58)	256 (62)	648 (70)	487 (47)	<.0001	.2334
	Ace inhibitor	1250 (41)	264 (39)	216 (52)	496 (53)	274 (27)	<.0001	.0216
	Insulin	478 (16)	93 (14)	92 (22)	162 (17)	131 (13)	<.0001	.2952
	Clonidine	115 (4)	28 (4)	12 (3)	49 (5)	26 (3)	.0107	.8035
Type of surgery	Aorta	232 (8)	78 (11)	8 (2)	98 (11)	48 (5)	<.0001	.008
	Carotid	875 (29)	165 (24)	160 (39)	350 (38)	200 (19)		
	Amputation	867 (28)	164 (24)	99 (24)	175 (19)	429 (42)		
	Bypass	1088 (36)	278 (41)	147 (36)	309 (33)	354 (34)		
RCRI	0	1223 (40)	288 (42)	159 (38)	230 (25)	546 (53)	<.0001	.5392
	1	1005 (33)	219 (32)	143 (35)	364 (39)	279 (27)		
	2	598 (20)	125 (18)	85 (21)	233 (25)	155 (15)		
	3	200 (7)	46 (7)	25 (6)	84 (9)	45 (4)		
	≥4	36 (1)	7 (1)	2 (0)	21 (2)	6 (1)		
Year of surgery	1998	544 (18)	126 (18)	60 (14)	74 (8)	284 (28)	<.0001	.3105
	1999	463 (15)	111 (16)	63 (15)	100 (11)	189 (18)		
	2000	420 (13)	87 (13)	55 (13)	123 (13)	155 (15)		
	2001	407 (13)	84 (12)	63 (15)	125 (13)	135 (13)		
	2002	374 (12)	81 (12)	55 (13)	139 (15)	99 (10)		
	2003	371 (12)	85 (13)	56 (14)	153 (16)	77 (7)		
	2004	407 (13)	96 (14)	46 (11)	183 (20)	82 (8)		
	2005	76 (3)	15 (2)	16 (4)	35 (4)	10 (1)		
Tobacco user	Yes	971 (32)	227 (33)	152 (37)	342 (37)	250 (24)	<.0001	.3914
	No	649 (21)	134 (20)	99 (24)	236 (25)	180 (17)		
	Null	1442 (47)	324 (47)	163 (39)	354 (38)	601 (58)		
Ethnicity	White	563 (18)	115 (17)	69 (17)	194 (21)	185 (18)	.2821	.9771
	Other	39 (1)	10 (1)	4 (1)	9 (1)	16 (2)		
	Unknown	2460 (80)	560 (82)	341 (82)	729 (78)	830 (81)		

Note: P values for categorical variables were obtained with the chi-square test and for continuous variables with the Wilcoxon rank sum test. Propensity-adjusted P values were derived from Cochran-Mantel-Haenszel statistics.

IQR, interquartile range; RCRI, revised cardiac risk index; HTN, hypertension; CVA/TIA, cerebral vascular disease; CA, cancer; DM, diabetes; lipid, hyperlipidemia; COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease; CHF, congestive heart failure; CKD, chronic kidney disease; ACE, angiotensin-converting enzyme.

blocker alone, and a statin and beta-blocker in combination with using neither study drug, demonstrated that the combination of statins and beta-blockers had an HR over the whole study period of 0.43 (95% CI 0.36-0.51, $P < .0001$), statins alone had an HR of 0.59 (95% CI 0.48-0.72, $P < .0001$), and

beta-blockers alone had an HR of 0.71 (95% CI 0.61-0.83, $P < .0001$).

To clarify the effects of the study drugs on patients at different levels of risk, we stratified patients by the RCRI and evaluated the effects of the study drugs on mortality at 2 years, comparing the




FIGURE 1. Study drug use groups and overall univariate survival.




FIGURE 2. Statin and beta-blocker propensity models in quintiles and overall association with mortality.

results to a referent of taking no study drugs. The use of both a statin and a beta-blocker consistently produced a relative risk reduction (RRR) of approximately 50% with an NNT of 4-10, with highly statistically significant results for patients at all levels of risk (Table 5). As patient risk level increased, the NNT decreased, consistent with higher-risk patients benefiting most from combination therapy with statins and beta-blockers.

In addition, the range of outcomes can be clearly seen for both patient-specific risk level and study drug use. For example, overall mortality at 2

TABLE 5
RCRI, Study Drugs, and Reduction in 2-Year Univariate Mortality^a

RCRI	Drug	N (Deaths)	Mortality	NNT	RRR	P value
0	None	546 (176)	0.19			
	BB	288 (73)	0.14	20	0.27	.0023
	Statin	159 (30)	0.12	14	0.39	<.0001
1	Statin+BB	230 (23)	0.09	10	0.54	<.0001
	None	279 (130)	0.28			
	BB	219 (71)	0.21	14	0.26	.0028
2	Statin	143 (41)	0.17	10	0.37	<.0001
	Statin+BB	364 (73)	0.13	7	0.53	<.0001
	None	155 (100)	0.43			
≥ 3	BB	125 (60)	0.33	10	0.23	.0045
	Statin	85 (42)	0.28	7	0.35	<.0001
	Statin+BB	233 (72)	0.22	5	0.50	<.0001
≥ 3	None	51 (39)	0.59			
	BB	53 (29)	0.47	9	0.20	.0296
	Statin	27 (14)	0.41	6	0.31	.0014
≥ 3	Statin+BB	105 (52)	0.32	4	0.46	<.0001

None, no statin or beta-blocker; BB, beta-blocker.

^aTwo-year mortality was estimated from Cox regression.

years for all patients was 22%. For the study drugs, mortality ranged from 16% for patient who used both a statin and a beta-blocker to 27% for those patients who used neither study drug. The use of the RCRI showed that the healthiest patients who were taking both a statin and a beta-blocker did the best, with a 2-year mortality of 9%, compared with the sickest patients who were taking neither study drug, whose 2-year mortality was 59%. Use of both study drugs by the sickest patients was associated with a reduction in 2-year mortality to 32% ($P < .0001$; Table 5).

Propensity Score Analysis of Use of Combination Study Drugs

Because there was very limited literature to guide us in the use of propensity score analysis of multiple treatment groups, we performed these analyses in an exploratory manner. There were significant differences between combination statin and beta-blocker users and nonusers. These differences became insignificant after adjusting for propensity score, except for the 5 variables previously mentioned, which were added to the model as potential confounders (Table 4). The propensity-adjusted Cox regression model comparing use of each study drug alone and in combination with taking neither over the whole study period still showed an association with decreased mortality. The combination of statins and beta-blockers had an HR of 0.56 (95% CI

TABLE 6
RCRI, Study Drugs, and Reduction in 2-Year Propensity-Adjusted Mortality^a

RCRI	Drug	N (Deaths)	Mortality	NNT	RRR	P value
0	None	546 (176)	0.14			
	BB	288 (73)	0.11	47	0.16	.3778
	Statin	159 (30)	0.11	40	0.19	.2902
	Statin+BB	230 (23)	0.08	20	0.38	.0184
1	None	279 (130)	0.21			
	BB	219 (71)	0.17	32	0.15	.2837
	Statin	143 (41)	0.17	27	0.18	.1969
	Statin+BB	364 (73)	0.13	14	0.37	.0038
2	None	155 (100)	0.29			
	BB	125 (60)	0.25	24	0.15	.3295
	Statin	85 (42)	0.24	20	0.17	.2396
	Statin+BB	233 (72)	0.18	10	0.36	.0077
≥ 3	None	51 (39)	0.42			
	BB	53 (29)	0.37	19	0.13	.3553
	Statin	27 (14)	0.36	16	0.15	.2653
	Statin+BB	105 (52)	0.28	8	0.33	.0106

None, no statin or beta-blocker; BB, beta-blocker.

^aTwo-year mortality was estimated from Cox regression.

0.42-0.74), $P < .0001$; statins alone had an HR of 0.79 (95% CI 0.62-0.99), $P = .0472$; and beta-blockers alone had an HR of 0.80 (95% CI 0.67-0.94), $P = .0183$.

Combination Study Drugs and Revised Cardiac Risk Index: Propensity Analysis

We performed the stratified Cox regression adjusted for the propensity scores for each level of RCRI and estimated 2-year mortality. The use of both a statin and a beta-blocker compared with using none was still consistently statistically significant, with an RRR of approximately 36% and an NNT of 8-20 for all levels of patient risk (Table 6). Possibly because of the reduced number of patients in each RCRI category, neither single-agent study drug compared with none showed a statistically significant decrease in mortality at any level of patient-specific risk (Table 6). Again, higher-risk patients benefited most from combination therapy.

Study Drug Timing: Subcohort Analysis

A subcohort analysis was performed to clarify the timing of the study drugs. Of the patients taking statins, 69 of 1346 (5.1%) took the drug before surgery only, 119 of 1346 (8.8%) took the drug after surgery only, and 1158 of 1346 (86%) took the drug both before and after surgery. Of the patients taking beta-blockers, 54 of 1617 (3.3%) took the drug be-

fore surgery only, 397 of 1617 (24.6%) took the drug after surgery only, and 1166 of 1617 (72.1%) took the drug both before and after surgery. The use of statins and beta-blockers had a correlation of 0.29 (contingency coefficient).

DISCUSSION

In this retrospective observational study we found that after vascular surgery the use of propensity-adjusted statins compared with no use of statins reduced long-term mortality over the study period by 22%, with a number needed to treat of 22, and the use of propensity-adjusted beta-blockers compared with no use also reduced long-term mortality, by 16%, with a number needed to treat of 30. There were no statistically significant differences between outcomes of statin users and beta-blocker users. In addition, using a propensity-adjusted combination of statin and beta-blockers compared with using neither decreased mortality overall by 44%, with a number needed to treat of 9. We focused on the use of outpatient drugs 30 days before or after surgery, as the timing of potentially beneficial medications has not been clearly established. Over time, more patients originally categorized as not taking a study drug began taking one, so that by 2 years after surgery, 58% of the patients were taking a statin, and 67% were taking a beta-blocker, compared with 44% and 53%, respectively, of the study cohort initially. This would have made it more difficult to demonstrate a difference between these 2 groups. As more patients ended up taking the study drugs over time than the originally identified study drug users, and a mortality difference was still demonstrated, there may be an increased advantage in taking the study drugs around the time of surgery. As our focus was on long-term postoperative mortality, which has not commonly been studied according to the literature, we preferred to also focus on long-term, chronic ambulatory use of the study drugs. We did perform a subcohort analysis of the timing of study drug use. This confirmed that this cohort predominately comprised long-term users of the study drugs who took the drug both before and after surgery. This study was not powered to comment on 30-day mortality.

Perioperative beta-blockers have been shown in retrospective cohort studies, case-control studies, randomized clinical trials, meta-analyses, and systematic reviews to decrease mortality and morbidity after noncardiac surgery. Although recent studies have not shown a benefit for more moder-

ate- to low-risk subjects,^{11,12} perioperative beta-blockers are still considered an indicator of health care quality in the United States.²⁵ At present, perioperative beta-blockers have an ACC/AHA class I indication (should be administered; Evidence level C) for patients undergoing vascular surgery with a positive stress test, and class IIa indication (reasonable to administer; Evidence level B) for vascular surgery patients with coronary heart disease or multiple clinical risk factors.²⁶ A recent observational study in noncardiac surgery patients demonstrated perioperative beta-blockers may be most helpful to prevent in-hospital death after surgery of patients with an RCRI ≥ 2 and may be unhelpful or harmful for patients with an RCRI ≤ 1 .²⁷ Our univariate RCRI findings did not agree, as we found all patients whatever their level of risk benefited from perioperative use of beta-blockers, alone or in combination. Our study population was older, had a higher RCRI, and underwent comparatively higher-risk surgery, we were investigating longer-term outcome, and we concentrated on ambulatory use of beta-blockers, which may have contributed to the divergence in findings. Our propensity-adjusted RCRI analysis did not show beta-blockers associated with any change in mortality at any patient risk level. This may be, in part, because of the reduced number of patients in the RCRI strata. RCRI stratum-specific analysis is limited by the number of patients and deaths in each RCRI stratum. For example, the power to detect a 2-year difference of 10% (or 5%) between statin users and nonusers is approximately 99% (66%), 99% (59%), 92% (42%), and 61% (23%) for RCRI = 0, 1, 2, and ≥ 3 , respectively.

Case-control and retrospective cohort studies and one randomized clinical trial have shown perioperative statins to decrease either short-term cardiovascular morbidity or mortality up to 30 days after surgery, and a limited number of retrospective cohort studies have shown reduced mortality for longer-term follow-up.^{14-18,28} There was one previous preliminary study of vascular surgery patients that demonstrated an additive benefit of using statins and beta-blockers up to 30 days after surgery. This additive effect was only observed in patients with an RCRI ≥ 3 .²⁹ The results of our longer-term follow-up study of a larger cohort did not agree. Compared with patients who did not take a statin or a beta-blocker, those patients who took both study drugs decreased their relative risk of mortality by approximately 36% in propensity-

adjusted analysis and by about 50% in univariate analysis, regardless of patient-specific risk level. For example, in the propensity-adjusted analysis, the healthiest patients with an RCRI of 0 who took both study drugs had lower mortality than patients who took neither study drug, 8% versus 14%, a 38% relative reduction in mortality, with a number needed to treat of 20 ($P = .0184$).

In addition, the use of the RCRI for the first time highlighted the divergent long-term mortality rates for patient-specific risk levels and the striking long-term associations of the perioperative use of ambulatory statins, beta-blockers, and both drugs in combination with improved long-term mortality. The long-term use of the study drugs may indeed help all patients with atherosclerotic vascular disease, regardless of surgery. However, vascular surgery presents an opportunity for medical intervention, and our results are most applicable for these patients. In addition, the perioperative state has a unique physiology of acute and intense inflammation and thrombosis. Beta-blockers and statins have antiadrenergic, anti-inflammatory, and anti-thrombotic properties that may be beneficial during this high-risk state.

Our findings should be viewed with some caution. The use of ICD-9 codes and demographic data is dependent on the documentation and coding of comorbidities in the medical record and database. The use of statins and beta-blockers was not random, and patients who took statins and beta-blockers were different than those who did not. We used rigorous propensity and multivariate analysis, including controlling for clonidine, which has been shown to decrease death after vascular surgery.³⁰ We also controlled for serum albumin level, which has been shown to be a leading predictor of postoperative death.³¹ We further separately stratified patients by RCRI, as this was a powerful predictor of death in the univariate analysis, but because of the retrospective nature of the study, unmeasured confounders may exist. Only 1% of the study patients were women, which is a limitation of the study. This administrative database is also limited by not having information on tobacco use for 47% of the patients and by not knowing ethnicity for 80% of the patients.

The use of perioperative statins and beta-blockers used alone or in combination was associated with a reduction in long-term mortality for vascular surgery patients, and combination use benefited patients at all levels of risk. Higher-risk patients

benefited most by taking both study drugs. These findings extend prior data, add to the natural history of long-term postoperative outcomes, and also support clinical trials that would evaluate the prospective use of both these medications in vascular surgery patients with attention to patient-specific risk level. Until the results of 2 randomized controlled trials become available, which may further clarify the use of perioperative statins and beta-blockers in noncardiac, and noncardiac vascular surgery,^{13,32} the use of statins and beta-blockers should be considered for all patients undergoing vascular surgery. In addition, long-term use of statins and beta-blockers for all patients with atherosclerotic vascular disease should be considered.³³

Address for correspondence and reprint requests: Thomas Barrett, MD, 3710 SW US VA Hospital Rd., Portland VAMC (P3MED), Portland, OR 97207-1034; E-mail: barretth@ohsu.edu

Received 24 March 2006; revisions received 9 November 2006; accepted 17 November 2006.

REFERENCES

1. McFalls EO, Ward HB, Santilli S, Scheftel M, Chesler E, Doliszny KM. The influence of perioperative myocardial infarction on long-term prognosis following elective vascular surgery. *Chest*. 1998;113:681-686.
2. Feinglass J, Pearce WH, Martin GJ, et al. Postoperative and amputation-free survival outcomes after femorodistal bypass grafting surgery: findings from the Department of Veterans Affairs National Surgical Quality Improvement Program. *J Vasc Surg*. 2001;34:283-290.
3. Fleisher LA, Eagle KA, Shaffer T, Anderson GF. Perioperative- and long-term mortality rates after major vascular surgery: the relationship to preoperative testing in the medicare population. *Anesth Analg* 1999;89:849-855.
4. Kazmers A, Kohler TR. Very late survival after vascular surgery. *J Surg Res*. 2002;105(2):109-114.
5. Mays BW, Towne JB, Fitzpatrick CM, et al. Women have increased risk of perioperative myocardial infarction and higher long-term mortality rates after lower extremity arterial bypass grafting. *J Vasc Surg*. 1999;29:807-812; discussion 12-13.
6. Mangano DT, Browner WS, Hollenberg M, London MJ, Tubau JF, Tateo IM. Association of perioperative myocardial ischemia with cardiac morbidity and mortality in men undergoing noncardiac surgery. The Study of Perioperative Ischemia Research Group. *N Engl J Med*. 1990;323:1781-1788.
7. Mangano DT, Wong MG, London MJ, Tubau JF, Rapp JA. Perioperative myocardial ischemia in patients undergoing noncardiac surgery—II: Incidence and severity during the 1st week after surgery. The Study of Perioperative Ischemia (SPI) Research Group. *J Am Coll Cardiol*. 1991;17:851-857.
8. Mangano DT, Hollenberg M, Fegert G, et al. Perioperative myocardial ischemia in patients undergoing noncardiac surgery—I: Incidence and severity during the 4 day perioperative period. The Study of Perioperative Ischemia (SPI) Research Group. *J Am Coll Cardiol*. 1991;17:843-850.
9. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. *N Engl J Med*. 1996;335:1713-1720.
10. Poldermans D, Boersma E, Bax JJ, et al. The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery. Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. *N Engl J Med*. 1999;341:1789-1794.
11. Brady AR, Gibbs JS, Greenhalgh RM, Powell JT, Sydes MR. Perioperative beta-blockade (POBBLE) for patients undergoing infrarenal vascular surgery: results of a randomized double-blind controlled trial. *J Vasc Surg*. 2005;41:602-609.
12. Juul AB, Wetterslev J, Gluud C, et al. Effect of perioperative beta blockade in patients with diabetes undergoing major non-cardiac surgery: randomised placebo controlled, blinded multicentre trial. *BMJ*. 2006;332:1482.
13. Devereaux PJ, Beattie WS, Choi PT, et al. How strong is the evidence for the use of perioperative beta blockers in noncardiac surgery? Systematic review and meta-analysis of randomised controlled trials. *BMJ*. 2005;331:313-321.
14. Poldermans D, Bax JJ, Kertai MD, et al. Statins are associated with a reduced incidence of perioperative mortality in patients undergoing major noncardiac vascular surgery. *Circulation*. 2003;107:1848-1851.
15. Lindenaauer PK, Pekow P, Wang K, Gutierrez B, Benjamin EM. Lipid-lowering therapy and in-hospital mortality following major noncardiac surgery. *JAMA* 2004;291:2092-2099.
16. Durazzo AE, Machado FS, Ikeoka DT, et al. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. *J Vasc Surg*. 2004;39:967-975; discussion 75-6.
17. O'Neil-Callahan K, Katsimiglis G, Tepper MR, et al. Statins decrease perioperative cardiac complications in patients undergoing noncardiac vascular surgery: the Statins for Risk Reduction in Surgery (StaRRS) study. *J Am Coll Cardiol*. 2005;45:336-342.
18. Parker Ward R, Leeper NJ, Kirkpatrick JN, Lang RM, Sorrentino MJ, Williams KA. The effect of preoperative statin therapy on cardiovascular outcomes in patients undergoing infrainguinal vascular surgery. *Int J Cardiol*. 2005;104:264-268.
19. McFalls EO, Ward HB, Moritz TE, et al. Coronary-artery revascularization before elective major vascular surgery. *N Engl J Med*. 2004;351:2795-2804.
20. Page WF, Mahan CM, Kang HK. Vital status ascertainment through the files of the Department of Veterans Affairs and the Social Security Administration. *Ann Epidemiol*. 1996;6(2):102-109.
21. Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. *Circulation*. 1999;100:1043-1049.
22. D'Agostino R. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. *Stat Med*. 1998;17:2265-2281.

23. Austin PC, Mamdani MM. A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. *Stat Med.* 2006;25:2084-2106.
24. Huang IC, Frangakis C, Dominici F, Diette GB, Wu AW. Application of a propensity score approach for risk adjustment in profiling multiple physician groups on asthma care. *Health Serv Res* 2005;40(1):253-78.
25. Shojania KG DB, McDonald KM, Wachter RM. Making Health Care Safer: A Critical Analysis of Patient Safety Practices: Evidence Report/Technology Assessment. Rockville, Md: AHRQ; 2001. Report No. 43.
26. Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2006 guideline update on perioperative cardiovascular evaluation for noncardiac surgery: focused update on perioperative beta-blocker therapy: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery): developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society for Vascular Medicine and Biology. *Circulation.* 2006;113:2662-2674.
27. Lindenauer PK, Pekow P, Wang K, Mamidi DK, Gutierrez B, Benjamin EM. Perioperative beta-blocker therapy and mortality after major noncardiac surgery. *N Engl J Med.* 2005; 353:349-361.
28. Kertai MD, Boersma E, Westerhout CM, et al. Association between long-term statin use and mortality after successful abdominal aortic aneurysm surgery. *Am J Med.* 2004;116(2): 96-103.
29. Kertai MD, Boersma E, Westerhout CM, et al. A combination of statins and beta-blockers is independently associated with a reduction in the incidence of perioperative mortality and nonfatal myocardial infarction in patients undergoing abdominal aortic aneurysm surgery. *Eur J Vasc Endovasc Surg.* 2004;28:343-352.
30. Wijeyundera DN, Naik JS, Beattie WS. Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications: a meta-analysis. *Am J Med.* 2003;114:742-752.
31. Gibbs J, Cull W, Henderson W, Daley J, Hur K, Khuri SF. Preoperative serum albumin level as a predictor of operative mortality and morbidity: results from the National VA Surgical Risk Study. *Arch Surg.* 1999;134(1):36-42.
32. Schouten O, Poldermans D, Visser L, et al. Fluvastatin and bisoprolol for the reduction of perioperative cardiac mortality and morbidity in high-risk patients undergoing non-cardiac surgery: rationale and design of the DECREASE-IV study. *Am Heart J.* 2004;148:1047-1052.
33. Hirsch AT, Haskal ZJ, Hertzner NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. *Circulation.* 2006;113:e463-e654.